A research team from the University of Cologne and collaborators has now shown that RNA interference, or RNAi for short, which is known to be a viral defense mechanism, also prevents the ...
RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial of ARO-DUX4, the ...
- ARO-DIMER-PA is the first clinical candidate designed to silence the expression of two genes with a single RNAi molecule - In preclinical studies, ARO-DIMER-PA potently lowered serum PCSK9 and APOC3 ...
- ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data and detailed its plans to advance two next generation RNAi-based candidates, ...
Morning Overview on MSN
Study shows chemo drug azacitidine damages RNA in stressed cells
The chemotherapy drug azacitidine, a frontline treatment for blood cancers such as myelodysplastic syndromes and acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results